US4487930A - 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines - Google Patents
6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines Download PDFInfo
- Publication number
- US4487930A US4487930A US06/414,766 US41476682A US4487930A US 4487930 A US4487930 A US 4487930A US 41476682 A US41476682 A US 41476682A US 4487930 A US4487930 A US 4487930A
- Authority
- US
- United States
- Prior art keywords
- phthalazine
- triazolo
- tetrahydro
- pyrrolidinyl
- ethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Definitions
- the present invention relates to tetrahydrotriazolo[3,4-a]phthalazines having a (cyclic amino)alkylamino substituent at the 6-position. More particularly, it relates to compounds having the following general formula ##STR1## wherein R is hydrogen or lower alkyl of 1-4 carbon atoms; Alk is alkylene of 2-4 carbon atoms; m is 0 or 1; and n is 4 or 5; and the pharmaceutically acceptable acid addition salts thereof.
- the lower alkyl group referred to above can be exemplified by groups such as methyl, ethyl, propyl and butyl.
- the alkylene groups referred to above separate the nitrogens attached thereto by at least two carbon atoms and can be exemplified by ethylene, propylene, trimethylene or tetramethylene.
- the cyclic amino group contains only carbon and one nitrogen and the cyclic amines involved are 1-pyrrolidinyl or 1-piperidinyl, both optionally substituted with a methyl group.
- Preferred compounds of the present invention are those wherein Alk is ethylene.
- a further preferred embodiment are those compounds wherein Alk is ethylene and R is hydrogen.
- Acid addition salts of the amines of the present invention with pharmaceutically acceptable acids are equivalent to the amines for the purposes of this invention.
- Illustrative of such salts are the salts with inorganic acids such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids; with organic carboxylic acids such as, for example, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic and dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, salicylic, 4-aminosalicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, mandelic and like acids; and with organic sulfonic acids such as methanesulfonic acid and p-toluenesulfonic acid.
- the substituted tetrahydrotriazolo[3,4-a]phthalazine compounds as described above are bronchodilators and are thus useful for the treatment of bronchial disorders such as bronchial asthma.
- the present invention is further directed to a method of effecting bronchodilation.
- an effective bronchodilating amount of 1 or more substituted tetrahydrotriazolo[3,4-a]phthalazines of this invention is administered internally to a mammal in need thereof by a route effective to bring the compound into contact with the bronchial and tracheal tissues of the mammal.
- Administration can be carried out either by a parenteral route, such as by intravenous, intraperitoneal or intramuscular injection, or by introduction into the gastrointestinal tract via oral or rectal administration, for example, in order to bring about such contact via the blood stream, or by intratracheal administration, by inhalation of a solution in the form of a spray or by inhalation of an aerosol formulation.
- the effective bronchodilating amount of the compound that is, the amount sufficient to inhibit or alleviate bronchial spasm, depends on various factors such as the size, type and age of the animal to be treated, the particular compound or pharmacologically-acceptable salt employed, the route and frequency of administration, the severity of any spasm and the causative agent involved, and the time of administration.
- the dosage to be administered can be ascertained by conventional range finding techniques, for example, by observing the bronchodilator activity produced at different dosage rates.
- the compounds can be administered at dosage rates ranging from about 1 to about 200 milligrams of substituted tetrahydrotriazolo[3,4-a]phthalazine compound per kilogram of animal body weight with other ranges being from about 1 to about 100 or from 1 to about 50 milligrams per kilogram. It is generally desirable to administer individual dosages at the lowest amount which provides the desired protection from bronchial spasm consonant with a convenient dosing schedule. Dosage units adaptable to oral administration such as tablets, capsules, lozenges, elixirs, syrups and the like are generally preferred and the active compound can be formulated in conventional time release capsule or tablet formulations although injectable compositions or sprays and aerosols for inhalation are preferred when rapid action is desired.
- the active ingredient is preferably incorporated in a composition comprising a pharmaceutical carrier and from about 5 to about 90 percent by weight of the substituted tetrahydrotriazolo[3,4-a]phthalazine compound or a pharmaceutically-acceptable salt thereof.
- pharmaceutical carrier refers to known pharmaceutical excipients useful in formulating pharmaceutically active compounds for internal administration to animals, and which are substantially non-toxic and non-sensitizing under conditions of use.
- compositions can be prepared by known techniques for the preparation of tablets, capsules, lozenges, troches, suppositories, elixirs, syrups, emulsions, dispersions, wettable and effervescent powders, sterile injectable compositions and solutions for sprays, and can contain suitable excipients known to be useful in the preparation of the particular type of composition desired.
- suitable pharmaceutical carriers and formulation techniques are found in standard texts, such as Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.
- test compounds were administered to guinea pigs either orally or by intraperitoneal injection and the guinea pigs were challenged by exposure to a histamine aerosol, generally 1 hour later although several time periods can be used. Untreated animals collapsed when exposed to the histamine aerosol. In these operations, the animals were observed and collapse times were recorded. The collapse times observed were then compared statistically with control animals treated with water alone with the control group usually being a long-term cumulative control. When tested by the above procedure, the compounds of the present invention were found to produce a bronchodilating effect.
- the compounds of the present invention are conveniently prepared by the reaction of a 6-halo-7,8,9,10-tetrahydro-1,2,4-triazolo[3,4-a]phthalazine with an appropriate amine of the formula ##STR2## where Alk, m and n are defined as above.
- the 6-halo substituent is preferably chlorine although it can also be bromine.
- This 6-halo compound is reacted with an excess of the amine in an inert solvent medium. More specifically, the reaction is carried out at the boiling temperature under reflux.
- the solvent medium can actually be an excess of the amine used in the reaction or an inert organic solvent such as 2-methoxyethanol.
- the product is recovered by conventional procedures such as concentration under reduced pressure or by pouring the reaction mixture into ice water. The process usually gives the product as the free amine and this can be converted to the acid addition salts by standard procedures, e.g., dissolving the amine in ethanol and adding the anhydrous acid, whereupon the salt precipitates out
- Example 2 The procedure of Example 1 was repeated using 6-chloro-7,8,9,10-tetrahydro-1,2,4-triazolo[3,4-a]phthalazine and the appropriate amine. The product obtained was then reacted with hydrogen chloride according to the procedure described in the first paragraph of Example 2 to give the corresponding salt. In this way, the following compounds were obtained:
- 1-Chloro-4-hydrazino-5,6,7,8-tetrahydrophthalazine also nameable as 3-chloro-4,5-tetramethylene-6-hydrazino pyridazine
- the mixture was heated at the boiling temperature under reflux for 2 hours.
- the mixture was concentrated by evaporation under reduced pressure, and the oily residue mixed with saturated aqueous sodium bicarbonate solution.
- the resulting white solid was separated by filtration, washed with water and dried in air.
- the 6-chloro-7,8,9,10-tetrahydro-1,2,4-triazolo[3,4-a]phthalazine product was recrystallized from alcohol-hexane and found to melt at 124°-125° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/414,766 US4487930A (en) | 1982-09-07 | 1982-09-07 | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines |
GR72367A GR78970B (fr) | 1982-09-07 | 1983-09-02 | |
ZA836551A ZA836551B (en) | 1982-09-07 | 1983-09-02 | 6-((cyclic amino)alkylamino)tetrahydrotriazolo(3,4-a)phthalazines |
JP58160604A JPS5965092A (ja) | 1982-09-07 | 1983-09-02 | 6−〔(環状アミノ)アルキルアミノ〕−テトラヒドロトリアゾロ〔3,4−a〕フタラジン類 |
AT83108711T ATE23339T1 (de) | 1982-09-07 | 1983-09-05 | 6-( (cyclic amino) alkylamino )tetrahydrotriazolo(3,4-a)phtalazines |
AU18713/83A AU555725B2 (en) | 1982-09-07 | 1983-09-05 | 6-((cyclic amino) alkylamino)tetrahydrotriazolo (3,4-alpha) phthalazines |
PH29493A PH18334A (en) | 1982-09-07 | 1983-09-05 | 6- (cyclic amino)alkylamino tetrahydrotriazolo 3,4-a phtalazines |
ES525368A ES525368A0 (es) | 1982-09-07 | 1983-09-05 | Procedimiento para la preparacion de 6-((ciclico amino) alquilamino)tetrahidrotriazolo (3,4-a)ftalazinas |
NZ205493A NZ205493A (en) | 1982-09-07 | 1983-09-05 | 6-((cyclic amino))-alkylamino)-tetrahydro-triazolo(3,4-a)phthalazine derivatives |
EP83108711A EP0104506B1 (fr) | 1982-09-07 | 1983-09-05 | 6-((Aminocyclique)alkylamino)tétrahydrotriazolo(3,4-a)phtalazines |
IL69659A IL69659A (en) | 1982-09-07 | 1983-09-05 | 6-(2-(cyclic amino)ethylamino)tetrahydrotriazolo(3,4-a)phthalazines,their preparation and pharmaceutical compositions containing them |
DE8383108711T DE3367393D1 (de) | 1982-09-07 | 1983-09-05 | 6-((cyclic amino)alkylamino)tetrahydrotriazolo(3,4-a)phthalazines |
KR1019830004193A KR880002685B1 (ko) | 1982-09-07 | 1983-09-06 | 6-[(사이클릭아미노)-알킬아미노]-테트라하이드로 트리아졸로[3,4-a]프탈라진 및 이의 제조방법 |
IE2096/83A IE55908B1 (en) | 1982-09-07 | 1983-09-06 | 6-((cyclic amino)alkylamino)tetrahydrotriazolo(3,4-a)phthalazines |
CA000438466A CA1204753A (fr) | 1982-09-07 | 1983-09-06 | 6-[(amino cyclique) alkylamino] tetrahydrotriazolo [3,4-a] phtalazines |
DK404383A DK160310C (da) | 1982-09-07 | 1983-09-06 | Analogifremgangsmaade til fremstilling af 6-oe(cyclisk amino)ethylaminoaatetrahydrotriazolooe3,4-aaaphthalaziner eller farmaceutisk acceptable syreadditionssalte deraf |
NO833181A NO833181L (no) | 1982-09-07 | 1983-09-06 | Fremgangsmaate ved fremstilling av 6-((cyklisk amino)alkyl-amino)-tetrahydrotriazol(3,4-a)fthalaziner |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/414,766 US4487930A (en) | 1982-09-07 | 1982-09-07 | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines |
Publications (1)
Publication Number | Publication Date |
---|---|
US4487930A true US4487930A (en) | 1984-12-11 |
Family
ID=23642869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/414,766 Expired - Lifetime US4487930A (en) | 1982-09-07 | 1982-09-07 | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines |
Country Status (17)
Country | Link |
---|---|
US (1) | US4487930A (fr) |
EP (1) | EP0104506B1 (fr) |
JP (1) | JPS5965092A (fr) |
KR (1) | KR880002685B1 (fr) |
AT (1) | ATE23339T1 (fr) |
AU (1) | AU555725B2 (fr) |
CA (1) | CA1204753A (fr) |
DE (1) | DE3367393D1 (fr) |
DK (1) | DK160310C (fr) |
ES (1) | ES525368A0 (fr) |
GR (1) | GR78970B (fr) |
IE (1) | IE55908B1 (fr) |
IL (1) | IL69659A (fr) |
NO (1) | NO833181L (fr) |
NZ (1) | NZ205493A (fr) |
PH (1) | PH18334A (fr) |
ZA (1) | ZA836551B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783461A (en) * | 1983-07-12 | 1988-11-08 | Gruppo Lepetit S.P.A. | 3,6-disubstituted triazolo [3,4-A]phthalazine derivatives |
US6255305B1 (en) | 1996-07-25 | 2001-07-03 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011835A (en) * | 1990-02-07 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Substituted triazolopyridazines, pharmaceutical compositions and use |
US6989080B2 (en) * | 2003-06-19 | 2006-01-24 | Albany International Corp. | Nonwoven neutral line dryer fabric |
AU2010338038B2 (en) | 2009-12-31 | 2015-07-09 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Tricyclic compounds for use as kinase inhibitors |
WO2012098387A1 (fr) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim |
WO2013004984A1 (fr) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Composés tricycliques pour l'utilisation en tant qu'inhibiteurs de kinase |
WO2013005057A1 (fr) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Nouveaux composés |
WO2013005041A1 (fr) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Composés hétérocycliques tricycliques en tant qu'inhibiteurs de kinases |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2484629A (en) * | 1943-11-27 | 1949-10-11 | Squibb & Sons Inc | 2-sulfanilamido-4-alkoxymethyl-6-methyl-pyrimidines and their preparation |
FR1248409A (fr) * | 1957-06-13 | 1960-12-16 | Bellon Labor Sa Roger | Perfectionnements aux procédés de préparation de dérivés de la triazolo [4-3,b]pyridazine |
US3079392A (en) * | 1961-04-27 | 1963-02-26 | Pesson Marcel | Triazolo(4-3, b)pyridazines |
US3096329A (en) * | 1957-10-15 | 1963-07-02 | Sterling Drug Inc | Triazolo [b] pyridazines |
US3483193A (en) * | 1965-07-02 | 1969-12-09 | Boehringer & Soehne Gmbh | 5-nitrofuryl and 5-nitrothienyl compounds |
CA883836A (en) * | 1971-10-19 | H. De Ruiter Ernest | Selective hydrogenation of tri- and tetrazoloisquinolines | |
US3708848A (en) * | 1969-11-27 | 1973-01-09 | P Guinard | Method of manufacturing filter elements |
US3915968A (en) * | 1973-09-21 | 1975-10-28 | Lepetit Spa | Triazolopyridazines |
JPS5121197A (fr) * | 1974-08-16 | 1976-02-20 | Nippon Special Steel Co Ltd | |
US4016162A (en) * | 1974-08-27 | 1977-04-05 | Gruppo Lepetit S.P.A. | 6-Morpholino-3-substituted phenyl-S-triazolo[4,3-b]pyridazines |
DE2741763A1 (de) * | 1976-09-22 | 1978-03-23 | American Cyanamid Co | Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
US4136182A (en) * | 1976-05-26 | 1979-01-23 | The Dow Chemical Company | Triazolopyridazines used to alleviate bronchial spasms |
GB2061275A (en) * | 1979-10-29 | 1981-05-13 | Dow Chemical Co | Substituted-s-triazolo(4,3-b)pyridazines |
US4272535A (en) * | 1978-07-31 | 1981-06-09 | Schering Corporation | 2,4-[1H,3H,5H]-(1)-Benzopyrano-[2,3-d]-pyrimidinediones and their use as anti-allergy agents |
-
1982
- 1982-09-07 US US06/414,766 patent/US4487930A/en not_active Expired - Lifetime
-
1983
- 1983-09-02 JP JP58160604A patent/JPS5965092A/ja active Granted
- 1983-09-02 GR GR72367A patent/GR78970B/el unknown
- 1983-09-02 ZA ZA836551A patent/ZA836551B/xx unknown
- 1983-09-05 AT AT83108711T patent/ATE23339T1/de not_active IP Right Cessation
- 1983-09-05 NZ NZ205493A patent/NZ205493A/en unknown
- 1983-09-05 EP EP83108711A patent/EP0104506B1/fr not_active Expired
- 1983-09-05 DE DE8383108711T patent/DE3367393D1/de not_active Expired
- 1983-09-05 IL IL69659A patent/IL69659A/xx not_active IP Right Cessation
- 1983-09-05 AU AU18713/83A patent/AU555725B2/en not_active Ceased
- 1983-09-05 PH PH29493A patent/PH18334A/en unknown
- 1983-09-05 ES ES525368A patent/ES525368A0/es active Granted
- 1983-09-06 CA CA000438466A patent/CA1204753A/fr not_active Expired
- 1983-09-06 KR KR1019830004193A patent/KR880002685B1/ko not_active IP Right Cessation
- 1983-09-06 IE IE2096/83A patent/IE55908B1/en not_active IP Right Cessation
- 1983-09-06 NO NO833181A patent/NO833181L/no unknown
- 1983-09-06 DK DK404383A patent/DK160310C/da not_active IP Right Cessation
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA883836A (en) * | 1971-10-19 | H. De Ruiter Ernest | Selective hydrogenation of tri- and tetrazoloisquinolines | |
US2484629A (en) * | 1943-11-27 | 1949-10-11 | Squibb & Sons Inc | 2-sulfanilamido-4-alkoxymethyl-6-methyl-pyrimidines and their preparation |
FR1248409A (fr) * | 1957-06-13 | 1960-12-16 | Bellon Labor Sa Roger | Perfectionnements aux procédés de préparation de dérivés de la triazolo [4-3,b]pyridazine |
US3096329A (en) * | 1957-10-15 | 1963-07-02 | Sterling Drug Inc | Triazolo [b] pyridazines |
US3079392A (en) * | 1961-04-27 | 1963-02-26 | Pesson Marcel | Triazolo(4-3, b)pyridazines |
US3483193A (en) * | 1965-07-02 | 1969-12-09 | Boehringer & Soehne Gmbh | 5-nitrofuryl and 5-nitrothienyl compounds |
US3708848A (en) * | 1969-11-27 | 1973-01-09 | P Guinard | Method of manufacturing filter elements |
US3915968A (en) * | 1973-09-21 | 1975-10-28 | Lepetit Spa | Triazolopyridazines |
JPS5121197A (fr) * | 1974-08-16 | 1976-02-20 | Nippon Special Steel Co Ltd | |
US4016162A (en) * | 1974-08-27 | 1977-04-05 | Gruppo Lepetit S.P.A. | 6-Morpholino-3-substituted phenyl-S-triazolo[4,3-b]pyridazines |
US4136182A (en) * | 1976-05-26 | 1979-01-23 | The Dow Chemical Company | Triazolopyridazines used to alleviate bronchial spasms |
DE2741763A1 (de) * | 1976-09-22 | 1978-03-23 | American Cyanamid Co | Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
US4272535A (en) * | 1978-07-31 | 1981-06-09 | Schering Corporation | 2,4-[1H,3H,5H]-(1)-Benzopyrano-[2,3-d]-pyrimidinediones and their use as anti-allergy agents |
GB2061275A (en) * | 1979-10-29 | 1981-05-13 | Dow Chemical Co | Substituted-s-triazolo(4,3-b)pyridazines |
Non-Patent Citations (8)
Title |
---|
Basu, et al., "s-Triazolopyrimidines . . . ", J. Chem. Soc., 1963, 5660. |
Basu, et al., s Triazolopyrimidines . . . , J. Chem. Soc., 1963, 5660. * |
Davies, et al., "n. Anti-Bronchoconstrictor . . . ", Nature New Biology 234, 50, (1971). |
Davies, et al., n. Anti Bronchoconstrictor . . . , Nature New Biology 234, 50, (1971). * |
Lundina, et al., Chem. Abst. 67, 21884q, (1967). * |
Noller, Carl, Textbook of Organic Chemistry, W. B. Saunders, Philadelphia, (1966), p. 422. * |
Pollack, et al., ". . . Pyridazine Derivatives, " Tetrahedron, 22, 2073-2079, (1966). |
Pollack, et al., . . . Pyridazine Derivatives, Tetrahedron, 22, 2073 2079, (1966). * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783461A (en) * | 1983-07-12 | 1988-11-08 | Gruppo Lepetit S.P.A. | 3,6-disubstituted triazolo [3,4-A]phthalazine derivatives |
US6255305B1 (en) | 1996-07-25 | 2001-07-03 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
EA002436B1 (ru) * | 1996-07-25 | 2002-04-25 | Мерк Шарп Энд Домэ Лимитед | Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк |
Also Published As
Publication number | Publication date |
---|---|
PH18334A (en) | 1985-06-05 |
DK404383A (da) | 1984-03-08 |
NZ205493A (en) | 1985-09-13 |
NO833181L (no) | 1984-03-08 |
CA1204753A (fr) | 1986-05-20 |
DK404383D0 (da) | 1983-09-06 |
IL69659A (en) | 1986-08-31 |
DK160310C (da) | 1991-07-29 |
AU555725B2 (en) | 1986-10-09 |
EP0104506A1 (fr) | 1984-04-04 |
KR880002685B1 (ko) | 1988-12-20 |
JPH0378396B2 (fr) | 1991-12-13 |
ZA836551B (en) | 1984-04-25 |
KR840006247A (ko) | 1984-11-22 |
IE832096L (en) | 1984-03-07 |
EP0104506B1 (fr) | 1986-11-05 |
DK160310B (da) | 1991-02-25 |
ES8601985A1 (es) | 1985-12-01 |
GR78970B (fr) | 1984-10-02 |
DE3367393D1 (de) | 1986-12-11 |
ES525368A0 (es) | 1985-12-01 |
JPS5965092A (ja) | 1984-04-13 |
IL69659A0 (en) | 1983-12-30 |
ATE23339T1 (de) | 1986-11-15 |
IE55908B1 (en) | 1991-02-14 |
AU1871383A (en) | 1984-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4487930A (en) | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines | |
US4391806A (en) | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators | |
NZ195355A (en) | 7-substituted-6-amino-1,2,4-triazolo(4,3-b)pyridazines | |
EP0441339B1 (fr) | Triazolopyridazines substituées | |
US4578464A (en) | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds | |
US4391807A (en) | 6-Substituted tetrahydroimidazo[2,1-a]phthalazines and use as bronchodilators | |
EP0099080B1 (fr) | Tétrahydrotétrazolo(5,1-a)phthalazines substituées | |
CA1334294C (fr) | Imidazole(2,1-b)quinazoline-5(3h)-ones substituees et composes tricycliques apparentes | |
EP0276835B1 (fr) | Pyrazolothiopyranopyrazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DOW CHEMICAL COMPANY THE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:PEET, NORTON P.;ALEXANDER, CATHERINE A.;REEL/FRAME:004309/0578 Effective date: 19820901 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |